Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001933444 | SCV002201976 | uncertain significance | MHC class I deficiency | 2022-07-05 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. ClinVar contains an entry for this variant (Variation ID: 1426651). This variant has not been reported in the literature in individuals affected with TAPBP-related conditions. This variant is present in population databases (rs765383234, gnomAD 0.003%). This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 433 of the TAPBP protein (p.Ala433Thr). |
Ambry Genetics | RCV004671538 | SCV005167606 | uncertain significance | not specified | 2024-05-14 | criteria provided, single submitter | clinical testing | The c.1297G>A (p.A433T) alteration is located in exon 6 (coding exon 6) of the TAPBP gene. This alteration results from a G to A substitution at nucleotide position 1297, causing the alanine (A) at amino acid position 433 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |